CHO DP-12 clone#1934 [CHO DP-12, clone#1934 aIL8.92 NB 28605/14] (ATCC® CRL-12445)

Organism: Cricetulus griseus, hamster, Chinese  /  Tissue: ovary  / 

Permits and Restrictions

View Permits

Organism Cricetulus griseus, hamster, Chinese
Tissue ovary
Product Format frozen
Morphology fibroblast
Culture Properties adherent
Biosafety Level 1
Storage Conditions liquid nitrogen vapor phase
Images
Derivation
The clone#1934 aIL8.42 NB 28605/14 cell line was derived by co-transfecting the CHO cell line DP-12 using Lipofection with the vector p6G4V11N35E.choSD.10 designed to coexpress variable light and heavy regions of the murine 6G4.2.5 monoclonal antibody (ATCC HB-11722). Clones were selected in methotrexate.
Comments
The cells are reported to produce 250 mg/L recombinant human anti-IL-8. Both the clone#1933 (ATCC CRL-12444) and clone#1934 (ATCC CRL-12445) antibodies inhibit IL-8 binding to human neutrophils. They also show equivalent neutralizing capabilities to inhibiting IL-8 mediated human neutrophil chemotaxis. The mammalian expression plasmid, p6G4V11N35AchoSD.9 (identified as p6G425V11N35A.choSD is deposited as ATCC 209552).
Complete Growth Medium The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: 200 nM methotrexate, 0.002 mg/ml recombinant human insulin, Trace Elements A (Cellgro) to a final concentration of 0.1%, Trace Elements B (Cellgro) to a final concentration of 0.1%, fetal bovine serum to a final concentration of 10%
Subculturing
Volumes are given for a 75 cm2 flask. Increase or decrease the amount of dissociation medium needed proportionally for culture vessels of other sizes.
  1. Remove culture medium. Keep the floating cells to transfer with attached cells..
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:4 is recommended
Medium Renewal: Two to three times weekly
Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C
Isotype human IgG1
Name of Depositor Genetech, Inc.
Year of Origin 1934
References

Hsei V, et al. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,468,532 dated Oct 22 2002

Hsei V, et al. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,458,355 dated Oct 1 2002

Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,133,426 dated Oct 17 2000

Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,117,980 dated Sep 12 2000

Gonzalez TN, et al. Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies. US Patent 6,025,158 dated Feb 15 2000

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation
References

Hsei V, et al. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,468,532 dated Oct 22 2002

Hsei V, et al. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,458,355 dated Oct 1 2002

Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,133,426 dated Oct 17 2000

Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,117,980 dated Sep 12 2000

Gonzalez TN, et al. Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies. US Patent 6,025,158 dated Feb 15 2000